Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer
C. Lim, Ming‐Sound Tsao, Lisa W. Le et al. · Annals of Oncology · 2015
Cited by 246 works. doi:10.1093/annonc/mdv208
Authors
- Ming‐Sound Tsao
- Lisa W. Le
- Frances A. Shepherd
- Ronald D. Feld
- Ronald L. Burkes
- Geoffrey Liu
- Suzanne Kamel‐Reid
- D. Hwang
- Jeffrey Tanguay
- Gilda da Cunha Santos
- Natasha B. Leighl
References
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
- First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
- Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline
- Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop
- Tumour molecular profiling for deciding therapy—the French initiative